Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy

Erez Levanon; Rotem Karni; Ariel Feiglin; Adi Mogilevsky; Eli Kopel; Michal Barak

Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy

Erez Levanon (Inventor), Rotem Karni (Inventor), Ariel Feiglin (Inventor), Adi Mogilevsky (Inventor), Eli Kopel (Inventor), Michal Barak (Inventor)

Bar-Ilan University

Research output: Patent

Abstract

The invention relates to methods, compositions, and splicing modulating agents comprising nucleic acid sequences, specifically, antisense oligonucleotides and gene editing compounds. The splicing modulating agents of the invention are used in methods for producing neoantigens in subjects suffering from neoplastic disorders, by the induction of aberrant splicing events. The modulators of the invention are further used by the invention in enhancing immunotherapy.

Original language	English
Patent number	US20220098578A1
State	Published - 1 Mar 2022

Cite this

@misc{7ef8e68187c84e43ad6934d446e783b6,

title = "Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy",

abstract = "The invention relates to methods, compositions, and splicing modulating agents comprising nucleic acid sequences, specifically, antisense oligonucleotides and gene editing compounds. The splicing modulating agents of the invention are used in methods for producing neoantigens in subjects suffering from neoplastic disorders, by the induction of aberrant splicing events. The modulators of the invention are further used by the invention in enhancing immunotherapy.",

author = "Erez Levanon and Rotem Karni and Ariel Feiglin and Adi Mogilevsky and Eli Kopel and Michal Barak",

note = "US Patent App. 17/427,405; US20220098578A1",

year = "2022",

month = mar,

day = "1",

language = "الإنجليزيّة",

type = "Patent",

}

TY - PAT

T1 - Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy

AU - Levanon, Erez

AU - Karni, Rotem

AU - Feiglin, Ariel

AU - Mogilevsky, Adi

AU - Kopel, Eli

AU - Barak, Michal

N1 - US Patent App. 17/427,405

PY - 2022/3/1

Y1 - 2022/3/1

N2 - The invention relates to methods, compositions, and splicing modulating agents comprising nucleic acid sequences, specifically, antisense oligonucleotides and gene editing compounds. The splicing modulating agents of the invention are used in methods for producing neoantigens in subjects suffering from neoplastic disorders, by the induction of aberrant splicing events. The modulators of the invention are further used by the invention in enhancing immunotherapy.

AB - The invention relates to methods, compositions, and splicing modulating agents comprising nucleic acid sequences, specifically, antisense oligonucleotides and gene editing compounds. The splicing modulating agents of the invention are used in methods for producing neoantigens in subjects suffering from neoplastic disorders, by the induction of aberrant splicing events. The modulators of the invention are further used by the invention in enhancing immunotherapy.

UR - https://patents.google.com/patent/US20220098578A1/en

M3 - براءة الإختراع

M1 - US20220098578A1

ER -

Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy

Abstract

Other files and links

Fingerprint

Cite this